131 related articles for article (PubMed ID: 38752557)
1. Oral preexposure prophylaxis uptake, adherence, and persistence during periconception periods among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; Haberer JE; Baeten JM; Hendrix CW; Ware NC; Moodley P; Pillay M; Bennett K; Bassler J; Psaros C; Hurwitz KE; Bangsberg DR; Smit JA
AIDS; 2024 Jul; 38(9):1342-1354. PubMed ID: 38752557
[TBL] [Abstract][Full Text] [Related]
2. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
[TBL] [Abstract][Full Text] [Related]
3. High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
Matthews LT; Atukunda EC; Owembabazi M; Kalyebera KP; Psaros C; Chitneni P; Hendrix CW; Marzinke MA; Anderson PL; Isehunwa OO; Hurwitz KE; Bennett K; Muyindike W; Bangsberg DR; Haberer JE; Marrazzo JM; Bwana MB
PLoS Med; 2023 Feb; 20(2):e1004088. PubMed ID: 36795763
[TBL] [Abstract][Full Text] [Related]
4. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
[TBL] [Abstract][Full Text] [Related]
5. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
[TBL] [Abstract][Full Text] [Related]
7. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of HIV Preexposure Prophylaxis Among Young Pregnant Women from Rural KwaZulu-Natal, South Africa.
Vazquez L; Moll AP; Kacin A; Ndlovu NE; Shenoi SV
AIDS Patient Care STDS; 2019 May; 33(5):214-219. PubMed ID: 31067125
[TBL] [Abstract][Full Text] [Related]
9. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
[TBL] [Abstract][Full Text] [Related]
10. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial.
Mansoor LE; Yende-Zuma N; Baxter C; Mngadi KT; Dawood H; Gengiah TN; Samsunder N; Schwartz JL; Doncel GF; Abdool Karim Q
J Int AIDS Soc; 2019 Sep; 22(9):e25381. PubMed ID: 31507088
[TBL] [Abstract][Full Text] [Related]
11. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
[TBL] [Abstract][Full Text] [Related]
12. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
[TBL] [Abstract][Full Text] [Related]
13. Adherence challenges with daily oral pre-exposure prophylaxis during pregnancy and the postpartum period in South African women: a cohort study.
Joseph Davey D; Nyemba DC; Castillo-Mancilla J; Wiesner L; Norman J; Mvududu R; Mashele N; Johnson LF; Bekker LG; Gorbach P; Coates TJ; Myer L
J Int AIDS Soc; 2022 Dec; 25(12):e26044. PubMed ID: 36480171
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.
Beesham I; Mansoor LE; Joseph Davey DL; Palanee-Phillips T; Smit J; Ahmed K; Selepe P; Louw C; Singata-Madliki M; Kotze P; Heffron R; Parikh UM; Wiesner L; Rees H; Baeten JM; Beksinska M
J Acquir Immune Defic Syndr; 2022 Sep; 91(1):26-30. PubMed ID: 35972853
[TBL] [Abstract][Full Text] [Related]
15. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K;
Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146
[TBL] [Abstract][Full Text] [Related]
16. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.
Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C
JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359
[TBL] [Abstract][Full Text] [Related]
17. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.
Martin M; Vanichseni S; Suntharasamai P; Sangkum U; Mock PA; Chaipung B; Worrajittanon D; Leethochawalit M; Chiamwongpaet S; Kittimunkong S; Gvetadze RJ; McNicholl JM; Paxton LA; Curlin ME; Holtz TH; Samandari T; Choopanya K;
Lancet HIV; 2017 Feb; 4(2):e59-e66. PubMed ID: 27866873
[TBL] [Abstract][Full Text] [Related]
19. Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
Liu AY; Cohen SE; Vittinghoff E; Anderson PL; Doblecki-Lewis S; Bacon O; Chege W; Postle BS; Matheson T; Amico KR; Liegler T; Rawlings MK; Trainor N; Blue RW; Estrada Y; Coleman ME; Cardenas G; Feaster DJ; Grant R; Philip SS; Elion R; Buchbinder S; Kolber MA
JAMA Intern Med; 2016 Jan; 176(1):75-84. PubMed ID: 26571482
[TBL] [Abstract][Full Text] [Related]
20. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]